LncRNAs: key players and novel insights into diabetes mellitus

Xiaoyun He, Chunlin Ou, Yanhua Xiao, Qing Han, Hao Li and Suxian Zhou _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:71325-71341. https://doi.org/10.18632/oncotarget.19921

Metrics: PDF 2309 views  |   HTML 5303 views  |   ?  


Xiaoyun He1,2,*, Chunlin Ou3,*, Yanhua Xiao1, Qing Han1, Hao Li4 and Suxian Zhou1

1Department of Endocrinology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China

2Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China

3Cancer Research Institute, Central South University, Changsha 410078, China

4Department of Neurology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China

*These authors contributed equally to this work and share co-first authors

Correspondence to:

Suxian Zhou, email: [email protected]

Keywords: LncRNAs, diabetes mellitus, pancreatic β cells, insulin resistance, epigenetic regulation

Received: March 29, 2017     Accepted: July 19, 2017     Published: August 04, 2017


Long non-coding RNAs (LncRNAs) are a class of endogenous RNA molecules, which have a transcribing length of over 200 nt, lack a complete functional open reading frame (ORF), and rarely encode a functional short peptide. Recent studies have revealed that disruption of LncRNAs levels correlates with several human diseases, including diabetes mellitus (DM), a complex multifactorial metabolic disorder affecting more than 400 million people worldwide. LncRNAs are emerging as pivotal regulators in various biological processes, in the progression of DM and its associated complications, involving pancreatic β-cell disorder, insulin resistance, and epigenetic regulation, etc. Further investigation into the mechanisms of action of LncRNAs in DM will be of great value in the thorough understanding of pathogenesis. However, prior to successful application of LncRNAs, further search for molecular biomarkers and drug targets to provide a new strategy for DM prevention, early diagnosis, and therapy is warranted.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19921